Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Converting Ropinirole IR to CR in RLS
NCT00256854Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ropinirole in restless legs syndrome (RLS) (6 cohorts), sponsored by GSK. Primary endpoint: Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR up to 5 weeks. Started Nov 2005; status: completed.
02
Drugs
ropinirole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00256854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256854.